Inloggad som:
NMDSG14-B-2
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
NMDSG14-B-2
A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syndrome - MDS
A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syndrome - MDS
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast av: Anita Björk (2023-09-11)